NEW YORK, Nov. 1 (GenomeWeb News) - Caprion and AstraZeneca will collaborate to develop therapies for prostate cancer, Caprion Pharmaceuticals said today.
Under the agreement, AstraZeneca will evaluate prostate cancer drug targets discovered by Caprion and obtain exclusive, worldwide rights to develop and commercialize therapeutic applications for selected targets. Caprion will retain rights to other targets.
AstraZeneca will pay Caprion an unspecified amount for up-front payment and license fees. The company will make additional payments contingent on its meeting certain development and commercialization milestones.